Table 4.
The PPV of PI-RADS classification for PCa in the two cohorts with MRI-targeted biopsy.
| Chinese cohort (n = 114) |
Dutch cohort (n = 123) |
||||
|---|---|---|---|---|---|
| PI-RADS score (number) | PCa | PPV | PI-RADS score (number) | PCa | PPV |
| PI-RADS 2 (4) | 0 | 0 | PI-RADS 2 (0) | 0 | 0 |
| PI-RADS 3 (34) | 13 | 38.2% | PI-RADS 3 (28) | 10 | 35.7% |
| PI-RADS 4 (39) | 26 | 66.7% | PI-RADS 4 (51) | 36 | 70.6% |
| PI-RADS 5 (37) | 27 | 73.0% | PI-RADS 5 (44) | 43 | 97.7% |
| PI-RADS ≥3 (110) | 66 | 60.0% | PI-RADS ≥3 (123) | 89 | 72.4% |
MRI, magnetic resonance imaging; PCa, prostate cancer; PI-RADS, Prostate Imaging Reporting and Data System; PPV, positive predictive value.